fludarabine has been researched along with tacrolimus in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (35.42) | 29.6817 |
| 2010's | 27 (56.25) | 24.3611 |
| 2020's | 4 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Auerbach, AD; Boulad, F; Collins, N; George, D; Gillio, A; Kernan, NA; O'Reilly, RJ; Prasad, V; Regan, AD; Small, TN; Torok-Castanza, J | 1 |
| Fujioka, T; Hirabayashi, N; Ikegame, K; Kawakami, M; Murakami, M; Ogawa, H; Soma, T; Sugiyama, H; Takahashi, R; Takimoto, T; Tamaki, H | 1 |
| Anderlini, P; Cabanillas, FF; Champlin, RE; Donato, ML; Gajewski, JL; Giralt, SA; Hagemeister, FB; Ippoliti, C; Khouri, IF; Korbling, M; Lee, MS; McLaughlin, P; Okoroji, GJ; Saliba, RM; Younes, A | 1 |
| Fukiya, E; Kimura, S; Kobayashi, Y; Kuroda, J; Murotani, Y; Ozawa, M; Terao, K; Yoshikawa, T | 1 |
| Blume, KG; Edelstein, CL; Maloney, DG; Maris, MB; McSweeney, P; Nieto, Y; Parikh, CR; Sahebi, F; Sandmaier, BM; Schrier, RW; Storb, RF | 1 |
| Barón, A; Bearman, SI; Hawkins, T; Jones, RB; McSweeney, PA; Nieto, Y; Patton, N; Rabinovitch, R; Shpall, EJ; Spearing, R; Zeng, C | 1 |
| Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Khouri, IF; Korbling, M; Lekakis, L; Martin, T; Shpall, EJ | 1 |
| Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S | 1 |
| Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K | 1 |
| Anderlini, P; Champlin, RE; Couriel, DR; Giralt, SA; Jabbour, E; Khouri, IF; Rondon, G | 1 |
| Cordonnier, M | 1 |
| Azuma, T; Kami, M; Komatsu, T; Kusumi, E; Matsumura, T; Miura, Y | 1 |
| Ambinder, RF; Bolaños-Meade, J; Borrello, I; Brodsky, RA; Chen, AR; Flowers, M; Fuchs, EJ; Gooley, TA; Harrington, E; Huff, CA; Jones, RJ; Kaup, M; Leffell, MS; Luznik, L; Matsui, W; O'Donnell, PV; Piantadosi, S; Powell, JD; Sandmaier, BM; Storb, RF; Symons, HJ; Warnock, S; Zahurak, M | 1 |
| Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ | 1 |
| Imataki, O; Ishida, T; Kitanaka, A; Kubota, Y; Ohbayashi, Y; Ohnishi, H; Tanaka, T | 1 |
| Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G | 1 |
| Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
| Acholonu, S; Champlin, R; Dabaja, B; Donato, M; Duvic, M; Hosing, C; Khouri, I; Richmond, H; Singh, L; Wei, W | 1 |
| Aoyama, M; Hashimoto, S; Itagaki, N; Iwanaga, T; Kawamura, M; Kazuta, T; Matsuda, M; Rai, S; Yamairi, N | 1 |
| Berman, DM; Buchwald, P; Han, D; Kenyon, NM; Kenyon, NS; Rothen, D; Willman, M | 1 |
| Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Zohren, F | 1 |
| Alyea, E; Antin, JH; Armand, P; Attar, E; Ballen, K; Boussiotis, VA; Brown, J; Cutler, C; Dey, BR; Herrera, M; Ho, V; Kao, G; Kim, HT; Koreth, J; Liney, D; McDonough, S; Reynolds, C; Ritz, J; Soiffer, R; Spitzer, T; Stevenson, K | 1 |
| Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL | 1 |
| Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM | 1 |
| Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S | 1 |
| Alvarnas, J; Bhatia, R; Cai, JL; Chang, K; Chao, J; Forman, SJ; Maegawa, R; Nakamura, R; O'Donnell, MR; Palmer, JM; Parker, PM; Pullarkat, V; Senitzer, D; Snyder, DS; Stein, AS; Stiller, T; Thomas, SH; Wang, S | 1 |
| Boyer, J; Frey, NV; Goldstein, SC; Hexner, EO; June, CH; Kumar, AJ; Levine, BL; Loren, AW; Luger, SM; Porter, DL; Reshef, R; Smith, J; Stadtmauer, EA | 1 |
| Calvo, K; Cole, K; Cuellar-Rodriguez, J; Freeman, A; Gea-Banacloche, J; Grossman, J; Hakim, F; Hickstein, DD; Holland, SM; Hughes, T; Parta, M; Zerbe, C | 1 |
| Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Bollard, C; Cuellar-Rodriguez, J; Freeman, AF; Gea-Banacloche, J; Grossman, J; Hickstein, DD; Holland, SM; Kong, HH; Moutsopoulos, N; Murdock, H; Parta, M; Shah, N; Stone, K; Su, H | 1 |
| Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B | 1 |
| Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Chammas, MJ; Cutler, CS; Glotzbecker, B; Ho, VT; Kim, HT; Koreth, J; Lange, PB; Nikiforow, S; Reynolds, CG; Ritz, J; Soiffer, RJ | 1 |
| Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q | 1 |
| Fujisawa, S; Ishibashi, D; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Matsumoto, K; Nakajima, Y; Tachibana, T; Tanaka, M; Yamamoto, E | 1 |
| Alyea, EP; Blum, W; Carter, S; Champlin, RE; Chen, YB; Devine, SM; Giralt, S; Hars, V; Horowitz, MM; Hsu, JW; Larson, RA; Linker, C; Mulkey, F; Owzar, K; Shea, TC; Sibley, AB; Slack, J; Soiffer, RJ; Stone, RM; Vij, R | 1 |
| Chang, W; Chen, F; Fu, C; Jin, Z; Ma, X; Miao, M; Qiu, H; Ruan, C; Sun, A; Tang, X; Wu, D; Xue, S | 1 |
| Ayala, E; Kharfan-Dabaja, MA; LaFave, D; Nishihori, T | 1 |
| Abu-Arja, R; Guilcher, GMT; Pai, V; Rangarajan, HG; Soni, S | 1 |
| Abraham, RS; Chadha, R; Kohli, S; Nivargi, S; Prakash Yadav, S; Rastogi, N; Thakkar, D | 1 |
| Ahmadi, AR; Akpinarli, B; Brandacher, G; Budihardjo, J; Etra, JW; Fidder, SAJ; Furtmüller, GJ; Lee, WPA; Lopez, J; Lough, DM; Miller, DT; Montgomery, RA; Nägele, F; Quan, A; Raimondi, G; Sun, Z; Vasilic, D; Wang, HD | 1 |
| Artz, A; Bishop, MR; Champlin, RE; Chen, J; Ciurea, SO; Gergis, U; Guarneri, D; Liu, H; Mayer, SA; Rondon, G; Shore, T; Srour, SA; Stock, W; van Besien, K | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; Pullarkat, V; Salhotra, A; Sandhu, K; Smith, E; Snyder, D; Stein, A; Tsai, NC | 1 |
| Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G | 1 |
| Ayash, L; Deol, A; Kim, S; Modi, D; Ratanatharathorn, V; Singh, V; Uberti, JP | 1 |
| Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA | 1 |
20 trial(s) available for fludarabine and tacrolimus
| Article | Year |
|---|---|
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Rituximab; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Living Donors; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Risk Factors; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
Topics: Adult; Aged; Antilymphocyte Serum; Feasibility Studies; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Salvage Therapy; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2007 |
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Topics: Adult; Aged; Blood Component Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Filgrastim; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Care; Postoperative Complications; Recombinant Proteins; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Premedication; Sirolimus; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Melphalan; Methotrexate; Middle Aged; Mycosis Fungoides; Myeloablative Agonists; Recurrence; Sezary Syndrome; Tacrolimus; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Living Donors; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
Topics: Adolescent; Adult; Allografts; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; GATA2 Transcription Factor; Genetic Diseases, Inborn; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2014 |
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Myeloablative Agonists; Prospective Studies; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2014 |
Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.
Topics: Adolescent; Adult; Busulfan; Child; Female; Graft Survival; Graft vs Host Disease; Guanine Nucleotide Exchange Factors; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Male; Methotrexate; Mutation; Myeloablative Agonists; Pilot Projects; Severe Combined Immunodeficiency; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Sirolimus; Stem Cell Transplantation; Survival Rate; Tacrolimus; Vidarabine | 2015 |
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
Topics: Adult; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Enzyme Inhibitors; Female; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neutrophils; Recovery of Function; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2019 |
28 other study(ies) available for fludarabine and tacrolimus
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.
Topics: Child, Preschool; Cyclophosphamide; Fanconi Anemia; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Depletion; Male; Recombinant Proteins; T-Lymphocytes; Tacrolimus; Vidarabine | 2000 |
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.
Topics: Adenoviridae Infections; Adenoviruses, Human; Antilymphocyte Serum; Bronchoalveolar Lavage Fluid; Busulfan; Cystitis; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Intellectual Disability; Male; Methylprednisolone; Mycophenolic Acid; Obesity; Peripheral Blood Stem Cell Transplantation; Prednisolone; Remission Induction; Siblings; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2002 |
Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adult; Aged; Behavior Therapy; Cohort Studies; Cyclosporine; Female; Glomerular Filtration Rate; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Stem Cell Transplantation; Tacrolimus; Time Factors; Vidarabine | 2004 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
[Visual cortes--is it a concern?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blindness, Cortical; Carmustine; Cathartics; Cholinergic Antagonists; Cisplatin; Cyclosporine; Dopamine Agents; Drug-Related Side Effects and Adverse Reactions; Hallucinations; Humans; Interferons; Serotonin Agents; Tacrolimus; Vidarabine; Vincristine; Visual Cortex | 2007 |
Graft-versus-myeloma effects in reduced-intensity cord blood transplantation.
Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Remission Induction; Retrospective Studies; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.
Topics: Adolescent; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
[Female case of successful engraftment after PBSCT from her HLA-haploidentical son for severe aplastic anemia during maintenance peritoneal dialysis].
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclophosphamide; Female; Graft Survival; Haploidy; HLA Antigens; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Peripheral Blood Stem Cell Transplantation; Peritoneal Dialysis, Continuous Ambulatory; Rabbits; Severity of Illness Index; Tacrolimus; Transplantation Conditioning; Vidarabine | 2010 |
Choice of immunosuppression influences cytomegalovirus DNAemia in cynomolgus monkey (Macaca fascicularis) islet allograft recipients.
Topics: Analgesics, Non-Narcotic; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus; Daclizumab; DNA, Viral; Ganciclovir; Humans; Immunoglobulin G; Immunosuppressive Agents; Islets of Langerhans Transplantation; Leukocytes; Macaca fascicularis; Organometallic Compounds; Organophosphorus Compounds; Retrospective Studies; Sirolimus; T-Lymphocytes; Tacrolimus; Transplantation, Homologous; Valganciclovir; Vidarabine | 2010 |
Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
Topics: Adult; Aged; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2011 |
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Sirolimus; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Transfusion; Male; Methotrexate; Middle Aged; Pilot Projects; Secondary Prevention; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Female; Graft Survival; Graft vs Host Disease; Haplotypes; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure.
Topics: Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Methotrexate; Mycophenolic Acid; Retrospective Studies; Siblings; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient.
Topics: Aged; Allografts; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Mycophenolic Acid; Tacrolimus; Transplantation Conditioning; Vidarabine | 2018 |
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Mycophenolic Acid; Premedication; Tacrolimus; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation.
Topics: Allografts; Antilymphocyte Serum; Child; Cyclophosphamide; Female; GATA2 Deficiency; GATA2 Transcription Factor; Graft vs Host Disease; Humans; Mutation; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Skin Diseases; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation.
Topics: Animals; Complement C4b; Composite Tissue Allografts; Desensitization, Immunologic; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Hindlimb; Immunosuppressive Agents; Isoantibodies; Male; Models, Animal; Myeloablative Agonists; Peptide Fragments; Rats, Inbred Lew; Skin Transplantation; Tacrolimus; Time Factors; Transplantation, Isogeneic; Vascularized Composite Allotransplantation; Vidarabine | 2018 |
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Topics: Aged; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2020 |
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Topics: Aged; Allografts; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Progression-Free Survival; Retrospective Studies; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2021 |
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
Topics: Busulfan; Graft vs Host Disease; Humans; Methotrexate; Primary Myelofibrosis; Recurrence; Tacrolimus | 2023 |